Meanwhile, accumulating evidence has indicated that aberrant OATP1B3 expression occurs in a significant proportion of tumors of non-hepatocyte origin, such as colon cancer, breast cancer, pancreatic cancer, and prostate cancer [10–14, 18, 20]. This evidence concerns the gene SLCO1B3 and prostate cancer.